Vistagen Therapeutics, Inc.
For the period ended Nov 13, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 13, 2025 · Filed Nov 13, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Program Highlights
Program Highlights
Fasedienol for the Acute Treatment of Social Anxiety Disorder
Earlier this month, Vistagen announced that the last patient completed the randomized, double-blinded portion of its PALISADE-3 Phase 3 clinical trial evaluating fasedienol for the acute treatment of social anxiety disorder.
Topline results from this randomized portion of the PALISADE-3 Phase 3 trial are expected in the fourth quarter of this calendar year.
A duplicate and concurrent Phase 3 trial, PALISADE-4, involves the same public speaking challenge study design as PALISADE-3. Topline results from the randomized, double-blinded portion PALISADE-4 are expected in the first half of 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.